0001415889-24-024117.txt : 20240930 0001415889-24-024117.hdr.sgml : 20240930 20240930203812 ACCESSION NUMBER: 0001415889-24-024117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20240930 DATE AS OF CHANGE: 20240930 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meckler Jeffrey A CENTRAL INDEX KEY: 0001506916 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 241340982 MAIL ADDRESS: STREET 1: 740 BROADWAY STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 form4-10012024_121008.xml X0508 4 2024-09-30 0001438533 Travere Therapeutics, Inc. TVTX 0001506916 Meckler Jeffrey A C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 true false false false 1 Common Stock 2024-09-30 4 M 0 40000 10.48 A 121000 D Common Stock 2024-09-30 4 S 0 40000 14.0581 D 81000 D Stock option (right to buy) 10.48 2024-09-30 4 M 0 40000 0 A 2024-10-08 Common Stock 40000 0 D This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024. The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. /s/ Elizabeth E. Reed, Attorney-in-Fact 2024-09-30